Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Spironolactone Ophthalmic Solution in Subjects With Dry Eye
NCT05995392Phase 1Unknown
- Sponsor
- Richard W. Yee, M.D., P.A.
- Start
- Aug 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of spironolactone in dry eye disease (DED) (2 arms), sponsored by Richard W. Yee, M.D., P.A. Primary endpoint: Symptom Assessment Questionnaire Dry Eye score at 4 weeks. Status: unknown.
02
Drugs
spironolactone
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05995392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05995392.